Experimental and Computational Insight into Human Mesenchymal Stem Cell Paracrine Signaling and Heterocellular Coupling Effects on Cardiac Contractility and Arrhythmogenicity

Circulation Research

Volumn 121, Issue 4, 2017, Pages 411-423

  Mayourian, Joshua ^a   Cashman, Timothy J ^a   Ceholski, Delaine K ^a   Johnson, Bryce V ^a,c   Sachs, David ^a   Kaji, Deepak A ^b   Sahoo, Susmita ^a   Hare, Joshua M ^d   Hajjar, Roger J ^a   Sobie, Eric A ^b   Costa, Kevin D ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b Department of Developmental and Regenerative Biology ^*  (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

cardiovascular disease; cell and tissue based therapy; computational biology; electrophysiology; excitation contraction coupling; exosomes; myocardial contraction

Indexed keywords

ADENOSINE TRIPHOSPHATASE; CALCIUM CHANNEL L TYPE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE;

ACTION POTENTIAL; ARRHYTHMOGENESIS; ARTICLE; CELL FUNCTION; CONTROLLED STUDY; ENDOPLASMIC RETICULUM; ENZYME ACTIVATION; ENZYME ACTIVITY; EXOSOME; HEART MUSCLE CONTRACTILITY; HUMAN; HUMAN CELL; MESENCHYMAL STEM CELL; PARACRINE SIGNALING; PRIORITY JOURNAL; PROTEOMICS; SARCOPLASMIC RETICULUM; ANIMAL; CARDIAC MUSCLE CELL; CELL CULTURE; CELL CULTURE TECHNIQUE; CELL DIFFERENTIATION; COMPUTER SIMULATION; EXCITATION CONTRACTION COUPLING; HEART ARRHYTHMIA; HEART CONTRACTION; MESENCHYMAL STROMA CELL; MOUSE; PATHOPHYSIOLOGY; PHYSIOLOGY; RAT;

ACTION POTENTIALS; ANIMALS; ARRHYTHMIAS, CARDIAC; CELL CULTURE TECHNIQUES; CELL DIFFERENTIATION; CELLS, CULTURED; COMPUTER SIMULATION; EXCITATION CONTRACTION COUPLING; HUMANS; MESENCHYMAL STROMAL CELLS; MICE; MYOCARDIAL CONTRACTION; MYOCYTES, CARDIAC; PARACRINE COMMUNICATION; RATS;

EID: 85021288314     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.117.310796     Document Type: Article

References (49)

1. Mozaffarian D, Benjamin EJ, Go AS, et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2015 update: a report from the American Heart Association. Circulation. 2015;131:e29-322. doi: 10.1161/ CIR.0000000000000152.
2. Gnecchi M, He H, Liang OD, Melo LG, Morello F, Mu H, Noiseux N, Zhang L, Pratt RE, Ingwall JS, Dzau VJ. Paracrine action accounts for marked protection of ischemic heart by Akt-modified mesenchymal stem cells. Nat Med. 2005;11:367-368. doi: 10.1038/nm0405-367.
3. Herrmann JL, Wang Y, Abarbanell AM, Weil BR, Tan J, Meldrum DR. Preconditioning mesenchymal stem cells with transforming growth factoralpha improves mesenchymal stem cell-mediated cardioprotection. Shock. 2010;33:24-30. doi: 10.1097/SHK.0b013e3181b7d137.
4. Schuleri KH, Feigenbaum GS, Centola M, Weiss ES, Zimmet JM, Turney J, Kellner J, Zviman MM, Hatzistergos KE, Detrick B, Conte JV, McNiece I, Steenbergen C, Lardo AC, Hare JM. Autologous mesenchymal stem cells produce reverse remodelling in chronic ischaemic cardiomyopathy. Eur Heart J. 2009;30:2722-2732. doi: 10.1093/eurheartj/ehp265.
5. Hatzistergos KE, Quevedo H, Oskouei BN, et al. Bone marrow mesenchymal stem cells stimulate cardiac stem cell proliferation and differentiation. Circ Res. 2010;107:913-922. doi: 10.1161/ CIRCRESAHA.110.222703.
6. Amado LC, Saliaris AP, Schuleri KH, St John M, Xie JS, Cattaneo S, Durand DJ, Fitton T, Kuang JQ, Stewart G, Lehrke S, Baumgartner WW, Martin BJ, Heldman AW, Hare JM. Cardiac repair with intramyocardial injection of allogeneic mesenchymal stem cells after myocardial infarction. Proc Natl Acad Sci USA. 2005;102:11474-11479. doi: 10.1073/ pnas.0504388102.
7. Amado LC, Schuleri KH, Saliaris AP, Boyle AJ, Helm R, Oskouei B, Centola M, Eneboe V, Young R, Lima JA, Lardo AC, Heldman AW, Hare JM. Multimodality noninvasive imaging demonstrates in vivo cardiac regeneration after mesenchymal stem cell therapy. J Am Coll Cardiol. 2006;48:2116-2124. doi: 10.1016/j.jacc.2006.06.073.
8. Karantalis V, DiFede DL, Gerstenblith G, et al. Autologous mesenchymal stem cells produce concordant improvements in regional function, tissue perfusion, and fibrotic burden when administered to patients undergoing coronary artery bypass grafting: The Prospective Randomized Study of Mesenchymal Stem Cell Therapy in Patients Undergoing Cardiac Surgery (PROMETHEUS) trial. Circ Res. 2014;114:1302-1310. doi: 10.1161/ CIRCRESAHA.114.303180.
9. Heldman AW, DiFede DL, Fishman JE, et al. Transendocardial mesenchymal stem cells and mononuclear bone marrow cells for ischemic cardiomyopathy: the TAC-HFT randomized trial. JAMA. 2014;311:62-73. doi: 10.1001/jama.2013.282909.
10. Hare JM, Traverse JH, Henry TD, Dib N, Strumpf RK, Schulman SP, Gerstenblith G, DeMaria AN, Denktas AE, Gammon RS, Hermiller JB Jr, Reisman MA, Schaer GL, Sherman W. A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. J Am Coll Cardiol. 2009;54:2277-2286. doi: 10.1016/j.jacc.2009.06.055.
11. Karantalis V, Hare JM. Use of mesenchymal stem cells for therapy of cardiac disease. Circ Res. 2015;116:1413-1430. doi: 10.1161/ CIRCRESAHA.116.303614.
12. Meyer GP, Wollert KC, Lotz J, Pirr J, Rager U, Lippolt P, Hahn A, Fichtner S, Schaefer A, Arseniev L, Ganser A, Drexler H. Intracoronary bone marrow cell transfer after myocardial infarction: 5-year follow-up from the randomized-controlled BOOST trial. Eur Heart J. 2009;30:2978-2984. doi: 10.1093/eurheartj/ehp374.
13. Hare JM, Fishman JE, Gerstenblith G, et al. Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial. JAMA. 2012;308:2369-2379. doi: 10.1001/ jama.2012.25321.
14. de Jong R, Houtgraaf JH, Samiei S, Boersma E, Duckers HJ. Intracoronary stem cell infusion after acute myocardial infarction: a meta-analysis and update on clinical trials. Circ Cardiovasc Interv. 2014;7:156-167. doi: 10.1161/CIRCINTERVENTIONS.113.001009.
15. Molina EJ, Palma J, Gupta D, Torres D, Gaughan JP, Houser S, Macha M. Reverse remodeling is associated with changes in extracellular matrix proteases and tissue inhibitors after mesenchymal stem cell (MSC) treatment of pressure overload hypertrophy. J Tissue Eng Regen Med. 2009;3:85-91. doi: 10.1002/term.137.
16. Tao H, Han Z, Han ZC, Li Z. Proangiogenic features of mesenchymal stem cells and their therapeutic applications. Stem Cells Int. 2016;2016:1314709. doi: 10.1155/2016/1314709.
17. Cashman TJ, Gouon-Evans V, Costa KD. Mesenchymal stem cells for cardiac therapy: practical challenges and potential mechanisms. Stem Cell Rev. 2013;9:254-265. doi: 10.1007/s12015-012-9375-6.
18. Ranganath SH, Levy O, Inamdar MS, Karp JM. Harnessing the mesenchymal stem cell secretome for the treatment of cardiovascular disease. Cell Stem Cell. 2012;10:244-258. doi: 10.1016/j.stem.2012.02.005.
19. Askar SF, Ramkisoensing AA, Atsma DE, Schalij MJ, de Vries AA, Pijnappels DA. Engraftment patterns of human adult mesenchymal stem cells expose electrotonic and paracrine proarrhythmic mechanisms in myocardial cell cultures. Circ Arrhythm Electrophysiol. 2013;6:380-391. doi: 10.1161/CIRCEP.111.000215.
20. DeSantiago J, Bare DJ, Semenov I, Minshall RD, Geenen DL, Wolska BM, Banach K. Excitation-contraction coupling in ventricular myocytes is enhanced by paracrine signaling from mesenchymal stem cells. J Mol Cell Cardiol. 2012;52:1249-1256. doi: 10.1016/j. yjmcc.2012.03.008.
21. Hwang HJ, Chang W, Song BW, et al. Antiarrhythmic potential of mesenchymal stem cell is modulated by hypoxic environment. J Am Coll Cardiol. 2012;60:1698-1706. doi: 10.1016/j.jacc.2012.04.056.
22. Valiunas V, Doronin S, Valiuniene L, Potapova I, Zuckerman J, Walcott B, Robinson RB, Rosen MR, Brink PR, Cohen IS. Human mesenchymal stem cells make cardiac connexins and form functional gap junctions. J Physiol. 2004;555:617-626. doi: 10.1113/jphysiol.2003.058719.
23. Shadrin IY, Yoon W, Li L, Shepherd N, Bursac N. Rapid fusion between mesenchymal stem cells and cardiomyocytes yields electrically active, non-contractile hybrid cells. Sci Rep. 2015;5:12043. doi: 10.1038/ srep12043.
24. Mayourian J, Savizky RM, Sobie EA, Costa KD. Modeling electrophysiological coupling and fusion between human mesenchymal stem cells and cardiomyocytes. PLoS Comput Biol. 2016;12:e1005014. doi: 10.1371/ journal.pcbi.1005014.
25. Britton OJ, Bueno-Orovio A, Van Ammel K, Lu HR, Towart R, Gallacher DJ, Rodriguez B. Experimentally calibrated population of models predicts and explains intersubject variability in cardiac cellular electrophysiology. Proc Natl Acad Sci USA. 2013;110:E2098-E2105. doi: 10.1073/ pnas.1304382110.
26. Zhou X, Bueno-Orovio A, Orini M, Hanson B, Hayward M, Taggart P, Lambiase PD, Burrage K, Rodriguez B. In vivo and in silico investigation into mechanisms of frequency dependence of repolarization alternans in human ventricular cardiomyocytes. Circ Res. 2016;118:266-278. doi: 10.1161/CIRCRESAHA.115.307836.
27. Wang D, Zhang F, Shen W, Chen M, Yang B, Zhang Y, Cao K. Mesenchymal stem cell injection ameliorates the inducibility of ventricular arrhythmias after myocardial infarction in rats. Int J Cardiol. 2011;152:314-320. doi: 10.1016/j.ijcard.2010.07.025.
28. Tang YL, Tang Y, Zhang YC, Qian K, Shen L, Phillips MI. Improved graft mesenchymal stem cell survival in ischemic heart with a hypoxia-regulated heme oxygenase-1 vector. J Am Coll Cardiol. 2005;46:1339-1350. doi: 10.1016/j.jacc.2005.05.079.
29. Citro L, Naidu S, Hassan F, Kuppusamy ML, Kuppusamy P, Angelos MG, Khan M. Comparison of human induced pluripotent stem-cell derived cardiomyocytes with human mesenchymal stem cells following acute myocardial infarction. PLoS One. 2014;9:e116281. doi: 10.1371/journal.pone.0116281.
30. Richardson JD, Bertaso AG, Psaltis PJ, Frost L, Carbone A, Paton S, Nelson AJ, Wong DT, Worthley MI, Gronthos S, Zannettino AC, Worthley SG. Impact of timing and dose of mesenchymal stromal cell therapy in a preclinical model of acute myocardial infarction. J Card Fail. 2013;19:342-353. doi: 10.1016/j.cardfail.2013.03.011.
31. Liu JF, Wang BW, Hung HF, Chang H, Shyu KG. Human mesenchymal stem cells improve myocardial performance in a splenectomized rat model of chronic myocardial infarction. J Formos Med Assoc. 2008;107:165-174. doi: 10.1016/S0929-6646(08)60130-8.
32. Iso Y, Spees JL, Serrano C, Bakondi B, Pochampally R, Song YH, Sobel BE, Delafontaine P, Prockop DJ. Multipotent human stromal cells improve cardiac function after myocardial infarction in mice without long-term engraftment. Biochem Biophys Res Commun. 2007;354:700-706. doi: 10.1016/j.bbrc.2007.01.045.
33. Mathieu E, Lamirault G, Toquet C, Lhommet P, Rederstorff E, Sourice S, Biteau K, Hulin P, Forest V, Weiss P, Guicheux J, Lemarchand P. Intramyocardial delivery of mesenchymal stem cell-seeded hydrogel preserves cardiac function and attenuates ventricular remodeling after myocardial infarction. PLoS One. 2012;7:e51991. doi: 10.1371/journal.pone.0051991.
34. Kazbanov IV, ten Tusscher KH, Panfilov AV. Effects of heterogeneous diffuse fibrosis on arrhythmia dynamics and mechanism. Sci Rep. 2016;6:20835. doi: 10.1038/srep20835.
35. Gomez JF, Cardona K, Martinez L, Saiz J, Trenor B. Electrophysiological and structural remodeling in heart failure modulate arrhythmogenesis. 2D simulation study. PLoS One. 2014;9:e103273. doi: 10.1371/journal. pone.0103273.
36. de Jong S, van Veen TA, van Rijen HV, de Bakker JM. Fibrosis and cardiac arrhythmias. J Cardiovasc Pharmacol. 2011;57:630-638. doi: 10.1097/ FJC.0b013e318207a35f.
37. Chang MG, Tung L, Sekar RB, Chang CY, Cysyk J, Dong P, Marbán E, Abraham MR. Proarrhythmic potential of mesenchymal stem cell transplantation revealed in an in vitro coculture model. Circulation. 2006;113:1832-1841. doi: 10.1161/CIRCULATIONAHA.105.593038.
38. Cashman TJ, Josowitz R, Gelb BD, Li RA, Dubois NC, Costa KD. Construction of defined human engineered cardiac tissues to study mechanisms of cardiac cell therapy. J Vis Exp. 2016:e53447.
39. Pedrotty DM, Klinger RY, Badie N, Hinds S, Kardashian A, Bursac N. Structural coupling of cardiomyocytes and noncardiomyocytes: quantitative comparisons using a novel micropatterned cell pair assay. Am J Physiol Heart Circ Physiol. 2008;295:H390-H400. doi: 10.1152/ ajpheart.91531.2007.
40. Cashman TJ, Josowitz R, Johnson BV, Gelb BD, Costa KD. Human engineered cardiac tissues created using induced pluripotent stem cells reveal functional characteristics of BRAF-mediated hypertrophic cardiomyopathy. PLoS One. 2016;11:e0146697. doi: 10.1371/journal. pone.0146697.
41. Schaaf S, Shibamiya A, Mewe M, Eder A, Stöhr A, Hirt MN, Rau T, Zimmermann WH, Conradi L, Eschenhagen T, Hansen A. Human engineered heart tissue as a versatile tool in basic research and preclinical toxicology. PLoS One. 2011;6:e26397. doi: 10.1371/journal.pone.0026397.
42. Kang K, Ma R, Cai W, Huang W, Paul C, Liang J, Wang Y, Zhao T, Kim HW, Xu M, Millard RW, Wen Z, Wang Y. Exosomes secreted from CXCR4 overexpressing mesenchymal stem cells promote cardioprotection via Akt signaling pathway following myocardial infarction. Stem Cells Int. 2015;2015:659890. doi: 10.1155/2015/659890.
43. Arslan F, Lai RC, Smeets MB, Akeroyd L, Choo A, Aguor EN, Timmers L, van Rijen HV, Doevendans PA, Pasterkamp G, Lim SK, de Kleijn DP. Mesenchymal stem cell-derived exosomes increase ATP levels, decrease oxidative stress and activate PI3K/Akt pathway to enhance myocardial viability and prevent adverse remodeling after myocardial ischemia/ reperfusion injury. Stem Cell Res. 2013;10:301-312. doi: 10.1016/j. scr.2013.01.002.
44. Del Poeta G, Venditti A, Del Principe MI, Maurillo L, Buccisano F, Tamburini A, Cox MC, Franchi A, Bruno A, Mazzone C, Panetta P, Suppo G, Masi M, Amadori S. Amount of spontaneous apoptosis detected by Bax/Bcl-2 ratio predicts outcome in acute myeloid leukemia (AML). Blood. 2003;101:2125-2131. doi: 10.1182/blood-2002-06-1714.
45. Ramireddy A, Brodt CR, Mendizabal AM, DiFede DL, Healy C, Goyal V, Alansari Y, Coffey JO, Viles-Gonzalez JF, Heldman AW, Goldberger JJ, Myerburg RJ, Hare JM, Mitrani RD. Effects of transendocardial stem cell injection on ventricular proarrhythmia in patients with ischemic cardiomyopathy: results from the POSEIDON and TAC-HFT trials. Stem Cells Transl Med. 2017;6:1366-1372. doi: 10.1002/sctm.16-0328.
46. Sarkar AX, Christini DJ, Sobie EA. Exploiting mathematical models to illuminate electrophysiological variability between individuals. J Physiol. 2012;590:2555-2567. doi: 10.1113/jphysiol.2011.223313.
47. Teng X, Chen L, Chen W, Yang J, Yang Z, Shen Z. Mesenchymal stem cell-derived exosomes improve the microenvironment of infarcted myocardium contributing to angiogenesis and anti-inflammation. Cell Physiol Biochem. 2015;37:2415-2424. doi: 10.1159/000438594.
48. Nguyen TP, Qu Z, Weiss JN. Cardiac fibrosis and arrhythmogenesis: the road to repair is paved with perils. J Mol Cell Cardiol. 2014;70:83-91. doi: 10.1016/j.yjmcc.2013.10.018.
49. White JW, Rassweiler A, Samhouri JF, Stier AC, White C. Ecologists should not use statistical significance tests to interpret simulation model results. OIKOS Syn Ecol. 2014;123:385-388